# US 2019/0315834 A1 · SIRP alpha-CD70 FUSION PROTEIN AND METHODS OF USE THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315834 A1
- Document ID: US20190315834A1
- Status: Published application
- Kind: A1
- Application number: 16/475,683
- Filed: 2018-01-04
- Published: 2019-10-17
- Earliest claimed: 2018-01-04
- Assignees: KAHR Medical Ltd.
- Inventors: Noam SHANI; Yosi GOZLAN; Michal DRANITZKI ELHALEL; Edwin BREMER; Ido KAMINSKY
- Web page: https://patentgrep.com/patent/US20190315834A1

## CPC

- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- A61P 35/00: Antineoplastic agents
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/21: containing a His-tag
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof.

## Claims

### Claim 1

A SIRPα-CD70 fusion protein being characterized by a single amino acid linker between said SIRPα and said CD70; and/or in a form of at least a homo-trimer.

### Claim 2

(canceled)

### Claim 3 (depends on 21)

The SIRPα-CD70 fusion protein of claim 21, wherein said at least homo-trimer is at least 140 kD in molecular weight as determined by SDS-PAGE.

### Claim 4 (depends on 1)

The SIRPα-CD70 fusion protein of claim 1, wherein the SIRPα-CD70 fusion protein comprises a linker between said SIRPα and said CD70.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 4)

The SIRPα-CD70 fusion protein of claim 4, wherein the linker is not an Fc domain of an antibody or a fragment thereof.

### Claim 8 (depends on 1)

The SIRPα-CD70 fusion protein of claim 1, wherein the linker is glycine.

### Claim 9 (depends on 1)

The SIRPα-CD70 fusion protein of claim 1, being soluble.

### Claim at position 9

10-11. (canceled)

### Claim 12 (depends on 1)

The SIRPα-CD70 fusion protein of claim 1, wherein said fusion protein is capable of at least one of:
(i) binding CD47 and CD27;
(ii) activating said CD27 signaling pathway in a cell expressing said CD27;
(iii) co-stimulating immune cells expressing said CD27; and/or
(iv) enhancing phagocytosis of pathologic cells expressing said CD47 by phagocytes compared to same in the absence of said SIRPα-CD70 fusion protein.

### Claim 13 (depends on 1)

The SIRPα-CD70 fusion protein of claim 1, wherein said SIRPα-CD70 fusion protein amino acid sequence comprises SEQ ID NO: 1.

### Claim 14 (depends on 1)

The SIRPα-CD70 fusion protein of claim 1, wherein said SIRPα-CD70 fusion protein amino acid sequence consists of SEQ ID NO: 1.

### Claim 15 (depends on 1)

A polynucleotide encoding the SIRPα-CD70 fusion protein of claim 1.

### Claim 16 (depends on 15)

A nucleic acid construct comprising the polynucleotide of claim 15, and a regulatory element for directing expression of said polynucleotide in a host cell.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A host cell comprising the SIRPα-CD70 fusion protein of claim 1.

### Claim 19 (depends on 15)

A method of producing a SIRPα-CD70 fusion protein, the method comprising expressing in a host cell the polynucleotide of claim 15.

### Claim 20 (depends on 19)

The method of claim 19, comprising isolating the fusion protein.

### Claim at position 19

21-22. (canceled)

### Claim 23 (depends on 1)

A method of treating a disease that can benefit from activating immune cells comprising administering to a subject in need thereof the SIRPα-CD70 fusion protein of claim 1.

### Claim 24

An article of manufacture identified for the treatment of a disease that can benefit from activating immune cells comprising a packaging material packaging a therapeutic agent for treating said disease; and a SIRPα-CD70 fusion protein, a polynucleotide encoding same, a nucleic acid construct encoding same or a host cell expressing same.

### Claim 25 (depends on 23)

The method of claim 23, wherein said disease comprises a hyper-proliferative disease, a disease associated with immune suppression or medication induced immunosuppression, or an infection.

### Claim 26

(canceled)

### Claim 27 (depends on 25)

The method of claim 25, wherein said hyper-proliferative disease comprises cancer.

### Claim 28

A method of treating cancer comprising administering to a subject in need thereof an anti-cancer agent; and a SIRPα-CD70 fusion protein, a polynucleotide encoding same, a nucleic acid construct encoding same or a host cell expressing same.

### Claim 29 (depends on 27)

The method of claim 27, wherein said cancer is selected from the group consisting of lymphoma, leukemia, colon cancer, pancreatic cancer, ovarian cancer, lung cancer and squamous cell carcinoma.

### Claim 30 (depends on 27)

The method of claim 27, wherein cells of said cancer express CD47.

### Claim at position 28

31-33. (canceled)

### Claim 34 (depends on 23)

The method of claim 23, wherein diseased cells of said subject express CD47.

### Claim at position 30

35-36. (canceled)

### Claim 37

A method of activating immune cells, the method comprising in-vitro activating immune cells in the presence of a SIRPα-CD70 fusion protein, a polynucleotide encoding same, a nucleic acid construct encoding same or a host cell expressing same.

### Claim 38 (depends on 37)

The method of claim 37, wherein said activating is in the presence of cells expressing CD47 or exogenous CD47.

### Claim 39 (depends on 38)

The method of claim 38, wherein said cells expressing said CD47 comprise pathologic cells.

### Claim at position 34

40-41. (canceled)

### Claim 42 (depends on 37)

The method of claim 37, wherein said activating is in the presence of an anti-cancer agent.

### Claim 43 (depends on 28)

The method of claim 28, wherein said anti-cancer agent comprises an antibody.

### Claim 44

(canceled)

### Claim 45 (depends on 43)

The method of claim 43, wherein said antibody is selected from the group consisting of rituximab, cetuximab and almetuzumab.

### Claim 46 (depends on 27)

The method of claim 27, comprising adoptively transferring said immune cells following said activating to a subject in need thereof.

### Claim 47

(canceled)

### Claim 48 (depends on 28)

The method of claim 28, wherein said SIRPα-CD70 fusion protein is characterized by a single amino acid linker between said SIRPα and said CD70 and/or being in a form of at least a homo-trimer.

### Claim at position 42

49-50. (canceled)
